1. Search Result
Search Result
Results for "

chemotherapeutic+agents

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

8

Natural
Products

10

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-14596
    Genistein
    Maximum Cited Publications
    88 Publications Verification

    NPI 031L

    EGFR Autophagy Apoptosis Endogenous Metabolite Cancer
    Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
    Genistein
  • HY-B0245
    Busulfan
    15+ Cited Publications

    DNA Alkylator/Crosslinker Apoptosis Infection Neurological Disease Inflammation/Immunology Cancer
    Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent .
    Busulfan
  • HY-19543
    Brusatol
    35+ Cited Publications

    NSC 172924

    Keap1-Nrf2 Apoptosis Cancer
    Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .
    Brusatol
  • HY-130751
    DODAP
    1 Publications Verification

    Liposome Inflammation/Immunology
    DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests). DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation .
    DODAP
  • HY-113914
    9-ING-41
    5+ Cited Publications

    Elraglusib

    GSK-3 Apoptosis Autophagy Cancer
    9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents .
    9-ING-41
  • HY-13585
    Carmustine
    5+ Cited Publications

    BCNU

    DNA Alkylator/Crosslinker Cancer
    Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
    Carmustine
  • HY-13761
    Teniposide
    10+ Cited Publications

    VM26

    Topoisomerase Cancer
    Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.
    Teniposide
  • HY-17419
    Ifosfamide
    5+ Cited Publications

    DNA Alkylator/Crosslinker Neurological Disease Cancer
    Ifosfamide is a CNS-penetrant alkylating chemotherapeutic agent with activity against a wide range of tumors.
    Ifosfamide
  • HY-147271

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b) is an antibody-drug conjugate linker (ADC linker) that binds to Nectin-4 polypeptides conjugated to chemotherapeutic agents. Mal-PEG8-Val-Ala-PAB-Exatecan can be used for cancer research .
    Mal-PEG8-Val-Ala-PAB-Exatecan
  • HY-19542
    C6 Ceramide
    3 Publications Verification

    C6-Cer; N-Hexanoylsphingosine

    Apoptosis Cancer
    C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide
  • HY-W014233
    L-Histidinol dihydrochloride
    1 Publications Verification

    Endogenous Metabolite Aminoacyl-tRNA Synthetase Cancer
    L-Histidinol dihydrochloride is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol dihydrochloride interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol dihydrochloride has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol dihydrochloride reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents .
    L-Histidinol dihydrochloride
  • HY-P99364
    Icrucumab
    1 Publications Verification

    Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

    VEGFR Apoptosis p38 MAPK Akt Endocrinology Cancer
    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .
    Icrucumab
  • HY-14596S

    NPI 031L-d4

    EGFR Autophagy Apoptosis Endogenous Metabolite Cancer
    Genistein-d4 is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis .
    Genistein-d4
  • HY-17013
    Dofequidar
    2 Publications Verification

    MS-209 free base

    P-glycoprotein Cancer
    Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .
    Dofequidar
  • HY-N3387

    Apoptosis NF-κB Akt MMP Inflammation/Immunology Cancer
    Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .
    Licoricidin
  • HY-114243

    NF-κB JNK Caspase Apoptosis Neurological Disease Cancer
    DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
    DpC
  • HY-14596R
    Genistein (Standard)
    Maximum Cited Publications
    88 Publications Verification

    NPI 031L (Standard)

    Reference Standards EGFR Autophagy Apoptosis Endogenous Metabolite Cancer
    Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
    Genistein (Standard)
  • HY-16965
    TH287
    3 Publications Verification

    DNA/RNA Synthesis Cancer
    TH287 is a potent and selective inhibitor of MTH1, with an IC50 of 0.8 nM. TH287 is highly selective towards MTH1, with no relevant inhibition of MTH2, NUDT5, NUDT12, NUDT14, NUDT16, dCTPase, dUTPase and ITPA at 100 μM. TH287 could act as a chemotherapeutic agent for cancer research .
    TH287
  • HY-150644
    S07-2010
    1 Publications Verification

    Aldose Reductase Cancer
    S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
    S07-2010
  • HY-W048495

    Nucleoside Antimetabolite/Analog Cancer
    2'-O-(2-Methoxyethyl)-uridine is a synthetic oligonucleotide conversed from uridine. 2'-O-(2-Methoxyethyl)-uridine has the potential for chemotherapeutic agents development .
    2'-O-(2-Methoxyethyl)-uridine
  • HY-108315

    6-Chrysenamine

    Drug Derivative Inflammation/Immunology Cancer
    6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer. 6-Aminochrysene is activated by CYP450 in rat liver .
    6-Aminochrysene
  • HY-B0245S

    DNA Alkylator/Crosslinker Apoptosis Inflammation/Immunology Cancer
    Busulfan-d8 is a deuterium labeled Busulfan. Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent .
    Busulfan-d8
  • HY-17013A
    Dofequidar fumarate
    2 Publications Verification

    MS-209

    P-glycoprotein Cancer
    Dofequidar fumarate (MS-209) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar fumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .
    Dofequidar fumarate
  • HY-108391

    N-Octanoyl-D-erythro-sphingosine

    Apoptosis PKC Autophagy Inflammation/Immunology Cancer
    C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
    C8-Ceramide
  • HY-B0245R

    DNA Alkylator/Crosslinker Apoptosis Reference Standards Inflammation/Immunology Cancer
    Busulfan (Standard) is the analytical standard of Busulfan. This product is intended for research and analytical applications. Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent .
    Busulfan (Standard)
  • HY-B1080A
    Tilorone
    2 Publications Verification

    Influenza Virus Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
    Tilorone
  • HY-17419S1

    Isotope-Labeled Compounds DNA Alkylator/Crosslinker Cancer
    Ifosfamide-d4 is the deuterium labeled Ifosfamide. Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors .
    Ifosfamide-d4
  • HY-N7029

    Others Cancer
    3',4',5',5,7-Pentamethoxyflavone, a natural flavonoid extracted from Rutaceae plants, sensitizes chemoresistant cancer cells to chemotherapeutic agents by inhibition of Nrf2 pathway .
    3',​4',​5',​5,​7-​Pentamethoxyflavone
  • HY-W048496

    Nucleoside Antimetabolite/Analog Cancer
    2'-O-(2-Methoxyethyl)-cytidine is a synthetic oligonucleotide derived from uridine. 2'-O-(2-Methoxyethyl)-cytidine has good hybridization properties and high stability, and can be used in the research of oligonucleotide chemotherapeutic agents .
    2'-O-(2-Methoxyethyl)-cytidine
  • HY-162022

    Enterovirus Virus Protease Infection
    BTA-188, a pyridazinyl oxime ether, is an orally active, potent inhibitor of rhinoviruses (HRV) and enterovirus (EV) 71 in vitro. BTA-188 inhibits HRV-2 replication with an IC50 of 0.8 nM and an IC90 of 11 nM. BTA-188 inhibits enterovirus with an IC50 of 82 and an IC90 of 109 nM. BTA-188 is a potential chemotherapeutic agent for infections caused by the viruses in the Picornaviridae .
    BTA-188
  • HY-136327

    DNA Alkylator/Crosslinker Cancer
    Phenylacetic acid mustard is the major metabolite of the cancer chemotherapeutic agent Chlorambucil (HY-13593). Chlorambucil is an alkylating agent with antitumor activity .
    Phenylacetic acid mustard
  • HY-119172

    Bacterial Infection Inflammation/Immunology Cancer
    NSC-60339, an efflux pump inhibitor and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent .
    NSC-60339
  • HY-19542S1

    C6-Cer-d11; N-Hexanoylsphingosine-d11

    Apoptosis Isotope-Labeled Compounds Cancer
    C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide-d11
  • HY-P11053

    HSP Cancer
    A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .
    A17 peptide
  • HY-W064342S

    Isotope-Labeled Compounds Endogenous Metabolite Aminoacyl-tRNA Synthetase Cancer
    L-Histidinol-d3 ((S)-2-Amino-3-(1H-imidazol-5-yl)propan-1-ol-d3) is the deuterium labeled L-Histidinol (HY-W014233). L-Histidinol is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents .
    L-Histidinol-d3
  • HY-13761R

    VM26 (Standard)

    Reference Standards Topoisomerase Cancer
    Teniposide (Standard) is the analytical standard of Teniposide. This product is intended for research and analytical applications. Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.
    Teniposide (Standard)
  • HY-120574

    ADC Payload Topoisomerase Cancer
    TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile .
    TH1338
  • HY-P11052

    HSP Cancer
    A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research .
    A8 peptide
  • HY-W665208

    Biochemical Assay Reagents Fungal Reactive Oxygen Species (ROS) Infection Neurological Disease Metabolic Disease Cancer
    Zapotin is a member of the polymethoxyflavones, which are natural polyphenols from the group of flavonoid. Zapotin exhibits antidepressant, anticancer, antifungal, and antioxidant activity. Zapotin is a chemopreventive and chemotherapeutic agent. Zapotin can result in a reduction of large aberrant crypt foci in CF-1 mouse model. Zapotin inhibits autophagosome formation. Zapotin has inhibitory activity in mouse mammary organ culture with an IC50 of 50 µg/mL .
    Zapotin
  • HY-119312

    PKC Cancer
    C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
    C8 Dihydroceramide
  • HY-177345

    Sigma Receptor Apoptosis Caspase Cancer
    SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer .
    SV119
  • HY-155222

    Epigenetic Reader Domain HDAC Cancer
    TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .
    TW9
  • HY-122888

    PI3K FGFR Autophagy CDK Reactive Oxygen Species (ROS) Cancer
    MPT0L145 is a PIK3C3/FGFR inhibitor, with a Kd value of 0.53 nM for PIK3C3. MPT0L145 decreases the phosphorylation of FGFR1, FGFR3 and their downstream proteins (FRS2, ERK and Akt). MPT0L145 induces G0/G1 cell cycle arrest and decreased protein levels of cyclin E. MPT0L145 promotes mitochondrial dysfunction, ROS production, and DNA damage. MPT0L145 is an autophagy inhibitor. MPT0L145 significantly sensitizes cancer cells to targeted or chemotherapeutic agents. MPT0L145 can be used for cancer research, such as bladder cancer and NSCLC .
    MPT0L145
  • HY-13585S

    BCNU-d8

    Isotope-Labeled Compounds DNA Alkylator/Crosslinker Cancer
    Carmustine-d8 is the deuterium labeled Carmustine. Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA .
    Carmustine-d8
  • HY-17419R

    Reference Standards DNA Alkylator/Crosslinker Cancer
    Ifosfamide (Standard) is the analytical standard of Ifosfamide. This product is intended for research and analytical applications. Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors.
    Ifosfamide (Standard)
  • HY-13585R

    BCNU (Standard)

    Reference Standards DNA Alkylator/Crosslinker Cancer
    Carmustine (Standard) is the analytical standard of Carmustine. This product is intended for research and analytical applications. Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
    Carmustine (Standard)
  • HY-17419S

    Isotope-Labeled Compounds DNA Alkylator/Crosslinker Cancer
    2’-Oxo Ifosfamide-d4 is the deuterium labeled Ifosfamide. Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors .
    2’-Oxo Ifosfamide-d4
  • HY-108251S

    DAMPA-d3

    Isotope-Labeled Compounds Antifolate Drug Metabolite Inflammation/Immunology
    Methotrexate metabolite-d3 is the deuterium labeled Methotrexate metabolite. Methotrexate metabolite (DAMPA), the active metabolite of Methotrexate. Methotrexate is a folic acid antagonist that is widely used as an immunosuppressant and chemotherapeutic agent .
    Methotrexate metabolite-d3
  • HY-162569

    Apoptosis Necroptosis Cancer
    Ru-TRZ2 is a potent ruthenium-based chemotherapeutic agent. Ru-TRZ2 induces apoptosis and necroptosis. Ru-TRZ2 shows antitumor activity .
    Ru-TRZ2
  • HY-W699643

    BNP-7787-d8

    Isotope-Labeled Compounds Drug Metabolite Cancer
    Dimesna-d8 (BNP-7787-d8) is the deuterium labeled Dimesna (HY-B1022). Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity.
    Dimesna-d8

온라인 문의

Your information is safe with us. * Required Fields.

호칭

 

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

 

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: